Trial Profile
An Open-label, Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Healthy Pregnant Participants
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Ad26.COV2 S (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Acronyms HORIZON 1
- Sponsors Janssen Vaccines and Prevention B.V
- 01 Feb 2024 Status changed from active, no longer recruiting to completed.
- 05 May 2023 Planned End Date changed from 30 May 2024 to 30 Nov 2023.
- 20 Dec 2022 Planned primary completion date changed from 16 Jan 2023 to 29 Nov 2023.